Rallybio Corporation
RLYBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Valued at $86.5M, RLYB is a micro-cap name in its sector. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Market Cap
$86.5M
Beta
-0.71
P/E (TTM)
2.03
P/E (Fwd)
-3.01
EPS (TTM)
$8.01
EPS (Fwd)
$-5.40
ROE
64.9%
ROA
-21.3%
Cash
$92.8M
Total Debt
$0
Free CF
-$14.3M
52W Change
268.7%
Annual Financials
Cash vs Debt
Where RLYB stands vs its 150-day and 200-day moving averages
As of the October 6, 2026 close, RLYB finished 20.37% above its 150-day moving average ($14.04) and 41.90% above its 200-day moving average ($11.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RLYB overbought or oversold?
At the October 6, 2026 close, RLYB's RSI(14) was 43.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Rallybio Corporation reports $92.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$14.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 64.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
RLYB's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RLYB.